---
schema_version: "secwatch.filing_event.v1"
accession: "0001401914-26-000025"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2026-05-14T20:01:25+00:00"
generated_at: "2026-05-14T21:02:56.894966+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience reports Q1 2026 cash $18.5M; first product revenue expected June 2026

## Summary
- Cash and equivalents $18.5M as of March 31; working capital ~$0.5M; revenue $0.2M from Gates Foundation services.
- Ovaprene Phase 3 trial receives second positive DSMB review; enrollment expected to complete in 2026 with 2027 primary endpoint analysis.
- DARE to PLAY sildenafil cream dispensing to commence summer 2026; pre-fulfillment prescribing active in all 50 states.
- Flora Sync LF5 commercial launch in June 2026; first-ever product revenue milestone expected that month.
- DARE-HPV Phase 2 study starting May 2026 with ARPA-H funding; DARE to RECLAIM targeting 2027 dispensing.

## SEC filing metadata
- accession: 0001401914-26-000025
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2026-05-14T20:01:25+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000025/0001401914-26-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000025/dare-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001401914-26-000025
- JSON: https://secwatch.observer/filing/0001401914-26-000025.json
- Plain text: https://secwatch.observer/filing/0001401914-26-000025.txt

## Key facts
- Earnings Releases
  Dare Bioscience, Inc. reported financial results for the quarter ended March 31, 2026.
  - Period: the quarter ended March 31, 2026
  - Result: reported results
  source text: On May 14, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026, a copy of which is furnished as Exhibit 99.1 to this report.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000140191426000025/0001401914-26-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.